Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425263 | 0.97 | PTPN11 (0.65) | PTPN11KCNH2EGFR | |
| SCHEMBL23425274 | 0.96 | PTPN11 (0.64) | PTPN11KCNH2EGFR | |
| SCHEMBL19785271 | 0.93 | PTPN11 (0.78) | PTPN11KCNH2EGFR | |
| SCHEMBL26981000 | 0.93 | PTPN11 (0.78) | PTPN11KCNH2EGFR | |
| SCHEMBL30296011 | 0.93 | PTPN11 (0.78) | PTPN11KCNH2EGFR | |
| SCHEMBL22694143 | 0.92 | PTPN11 (0.70) | PTPN11KCNH2EGFR | |
| SCHEMBL21154242 | 0.90 | PTPN11 (0.76) | PTPN11KCNH2EGFR | |
| SCHEMBL22694129 | 0.89 | PTPN11 (0.74) | PTPN11KCNH2EGFR | |
| SCHEMBL19785521 | 0.89 | PTPN11 (0.74) | PTPN11KCNH2EGFR | |
| SCHEMBL22694112 | 0.88 | PTPN11 (0.85) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | Revolution Medicines, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | PTPN1, PTPN18, PTPN7 | PTPN11 15/4885KCNH2 4135/4885EGFR 491/4885 |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | DUSP3, PTPRCAP, PTPN1 | PTPN11 32/4885KCNH2 4786/4885EGFR 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.